Daewoong takes a lead for anticancer ‘Samfenet’ on behalf of Samsung Bioepis
Daewoong Pharmaceutical(CEO Jong-Wook Lee) announced the company would launch ‘Samfenet,’ a Samsung Bioepis’ trastuzumab biosimilar on the 5th in Korea. Samfenet acquired approval from the Korean Ministry of Food and Drug Safety on 8 November 2017, and was registered in the list of insured produc...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
